Rheumatoid arthritis (RA) was causally linked to the development of idiopathic pulmonary fibrosis, with shared plasma factors CC motif chemokine ligand 2 (CCL2) and CXC motif chemokine ligand 2 (CXCL2 ...

Please provide your email address to receive an email when new articles are posted on . Kevzara is approved for polyarticular JIA in patients weighing 63 kg or greater. The drug is an IL-6 inhibitor ...

"According to our study, adult patients with JIA may benefit from revising their diagnosis. The diagnosis of adult-onset rheumatic disease expands the range of possible medical interventions. This is ...

Dosage in the pJIA patient population can be achieved by using the 200mg/1.14mL prefilled syringe. The Food and Drug Administration (FDA) has approved Kevzara ® (sarilumab), an interleukin-6 receptor ...

Please provide your email address to receive an email when new articles are posted on . DESTIN, Fla. — Understanding the subtypes of juvenile idiopathic arthritis can help adult and pediatric ...

The FDA has approved Tofidence, the first tocilizumab biosimilar in the United States, which will be used to treat rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic ...

SUGAR LAND, Texas--(BUSINESS WIRE)--FDA has authorized Hope Biosciences’ adipose-derived mesenchymal stem cells (HB-adMSCs) for use in the first pediatric clinical trial, to evaluate if intravenous ...

Rheumatoid arthritis (RA) is a common autoimmune disease, and approximately 30%-40% of patients develop pulmonary complications such as idiopathic pulmonary fibrosis (IPF), but the causal relationship ...

Celltrion USA is offering an 80 mg dose of Yuflyma (adalimumab-aaty), a high-concentration (100mg/ml) and citrate-free formulation of Humira (adalimumab) biosimilar, in the United States. Yuflyma is ...

Celltrion is offering Avtozma (tocilizumab-anoh) intravenous formulation, which is a biosimilar of Chugai Pharmaceutical’s Actemra. Avtozma is used to treat rheumatoid arthritis, giant cell arteritis, ...